Plain-English translation of NCT06075420 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a new heart stent called GENOSS DES to see how well it works when patients take blood-thinning medications for a shorter period after the stent is placed. This medication (called dual antiplatelet therapy) usually prevents blood clots around the stent. The study wants to learn if patients can safely stop these medications sooner than typical—after 3 months for stable heart disease or 6 months for acute heart attacks—without having problems.
Blood-thinning medications after stent placement can cause bleeding and are expensive, so doctors want to know if shorter treatment is safe. Real-world data from this medication in everyday patients is limited, so this study will help answer that important question.
You likely qualify if…
You likely don't qualify if…
You will receive the GENOSS stent as part of your regular heart care, then be followed for 12 months to track how you're doing. Researchers will monitor your health outcomes and check whether the shorter duration of blood-thinning medication is working well for you. You'll need to attend follow-up visits and share information about your health during this year-long observation period.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
South Korea
Sponsor
Genoss Co., Ltd.
Enrollment target
~1,000 participants
Started
August 2021
Primary completion
December 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
YoungJin Youn
Genoss Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.